Nick Paul Taylor

Biography for Nick Paul Taylor

Nick Taylor, UK Correspondent

Nick Taylor is a freelance journalist with more than six years' experience of reporting on the global biopharma industry. Since graduating with a biology degree from the University of York, Nick has written for numerous healthcare publications, including Nature BioPharma Dealmakers, Life Science Leader and Outsourcing-Pharma. You can contact him at ntaylor@fiercemarkets.com and follow him on Twitter at @NickPaulTaylor.

Articles by Nick Paul Taylor

GoBalto eyes Asian expansion after $12M Mitsui-led financing

Study startup specialist goBalto is preparing to up its game in Asia. The San Francisco, CA-based software developer outlined the strategy after raising $12 million from new backers, including Japan's Mitsui Global Investment.

Obama talks up precision meds, cybersecurity in SOTU speech

President Obama has pushed precision medicine and cybersecurity into the national consciousness and toward the top of the legislative agenda. Obama referred to both topics in his State of the Union address, but at this stage more is known about the cybersecurity plan.

$4B VC shop lays out its vision for the future of digital health

Anyone with a passing interest in tech startups is unlikely to be shocked by Silicon Valley VC Andreessen Horowitz listing digital health as one of its top 16 trends. But as one of the organizations with some power over how these trends play out, the reasoning behind Andreessen Horowitz's list makes for interesting reading.

BIO is preparing small biotechs for life in the social media maelstrom

Last year the campaign for Chimerix to give an experimental cancer drug to a 7-year-old gave biopharma firms another reason to be wary of the power of social media. Having seen Chimerix be engulfed by the social media maelstrom, BIO is working to equip small biotechs with the skills they will need if they find themselves in a similar situation.

Novartis teams with Qualcomm on $100M digital health fund

The deal gives Novartis access to the most active digital health VC team--Rock Health reports Qualcomm Ventures has struck 21 deals since 2011--and further strengthens the ties between the two companies.

10X Genomics exits stealth mode with $80M, plan to improve Illumina tech

10X Genomics has exited stealth mode with $80 million in VC funding and a plan to solve a significant sequencing problem without going head to head with Illumina. The Pleasanton, CA-based startup is set to unveil an add-on for Illumina sequencers that improves their ability to map long reads of DNA.

Personalis raises $33M to scale up pharma-facing genomics operation

Personalis has returned to the financing font ahead of a planned scaling up of its operations. The Menlo Park, CA-based genome sequencing and interpretation company has reported interest from pharma companies in its cancer services, a trend that helped persuade investors to give it $33 million in a Series C round.

J&J, IOM provide big boosts to data transparency agenda

The clinical trial data transparency movement was propelled forward by two major developments this week. On the same day, influential national academy the Institute of Medicine called for more systematic sharing of trial results and Johnson & Johnson agreed to extend its transparency initiative to include medical devices and diagnostics.

Genentech teams with Venter's HLI as Roche group continues genomics push

Having given a $60 million boost to 23andMe last week, Genentech has now turned to J. Craig Venter's Human Longevity for help sequencing and analyzing tens of thousands of genomes.

23andMe inks Pfizer deal, eyes 2015 resolution of FDA dispute

Days after unveiling a $60 million deal with Genentech, personal genomics pioneer 23andMe struck a new database-driven collaboration with Pfizer. There is even talk of a possible resolution with the FDA in 2015.